| NewAmsterdam Pharma Co N.V. |
Chief Commercial Officer |
Ordinary Shares |
43,000 |
$1,098,087 |
$25.54 |
07 Jan 2025 |
Direct |
| NewAmsterdam Pharma Co N.V. |
Chief Commercial Officer |
Option (right to buy) |
200,000 |
|
|
02 Jan 2025 |
Direct |
| Annexon, Inc. |
Director |
Stock Option (Right to Buy) |
55,000 |
|
|
05 Jun 2025 |
Direct |
| Akili, Inc. |
Director |
Stock Option (Right to Buy) |
22,000 |
|
|
02 May 2023 |
Direct |
| Apogee Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
14,461 |
|
|
17 Jun 2025 |
Direct |
| Biohaven Pharmaceutical Holding Co Ltd. |
CCO-Migraine & Common Disease |
Common Shares |
0 |
|
$148.50 |
03 Oct 2022 |
Direct |
| Biohaven Pharmaceutical Holding Co Ltd. |
CCO-Migraine & Common Disease |
Restricted Share Unit Award |
0 |
|
|
03 Oct 2022 |
Direct |
| Biohaven Pharmaceutical Holding Co Ltd. |
CCO-Migraine & Common Disease |
Stock Options (Right to Buy) |
0 |
|
|
03 Oct 2022 |
Direct |